Last reviewed · How we verify

Commercial ibuprofen

Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · Phase 3 active Small molecule

Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce the production of prostaglandins, thereby decreasing inflammation, pain, and fever.

Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce the production of prostaglandins, thereby decreasing inflammation, pain, and fever. Used for Mild to moderate pain, Fever reduction, Inflammation associated with headache, muscular aches, backache, minor arthritis pain, menstrual cramps, and common cold.

At a glance

Generic nameCommercial ibuprofen
Also known asCommercial IBU
SponsorJohnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
Drug classNonsteroidal anti-inflammatory drug (NSAID)
TargetCyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
ModalitySmall molecule
Therapeutic areaPain Management, Inflammation, Fever
PhasePhase 3

Mechanism of action

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively blocks COX-1 and COX-2 enzymes, which catalyze prostaglandin synthesis. By reducing prostaglandin levels in tissues, it suppresses inflammatory responses, alleviates pain signaling, and lowers body temperature set point. This mechanism makes it effective for mild to moderate pain and inflammatory conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results